TY - JOUR
T1 - Prophylaxis of CMV disease by ganciclovir (DHPG) in seronegative recipients of renal allograft from seropositive donors.
AU - Rondeau, E.
AU - Bourgeon, B.
AU - Peraldi, M. N.
AU - Lang, P.
AU - Buisson, C.
AU - Schulte, K. M.
AU - Weill, B.
AU - Sraer, J. D.
PY - 1992
Y1 - 1992
N2 - In an open-label randomized study of prophylactic treatment by ganciclovir, 23 seronegative recipients of kidney allograft from seropositive donors were randomized to receive from day 14 to day 28 after transplantation either no treatment (n = 11) or ganciclovir, 5 mg/kg twice daily (n = 12). Both groups were similar in age, immunosuppressive therapy, number of acute rejections and in steroid bolus. Seroconversion occurred in ten patients of the control group (91%) and in ten of the ganciclovir group (84%). CMV disease occurred in ten patients of the control group (91%) and in eight patients of the ganciclovir group (66%), three of whom had asymptomatic viraemia. The delay between transplantation and onset of CMV disease was significantly increased by ganciclovir prophylaxis (78.5 +/- 7.7 vs 46.5 +/- 7.5 days, P < 0.05). We conclude that in renal transplant recipients at risk of CMV disease, ganciclovir prophylaxis delays the onset of the disease and seems to decrease its incidence and its severity.
AB - In an open-label randomized study of prophylactic treatment by ganciclovir, 23 seronegative recipients of kidney allograft from seropositive donors were randomized to receive from day 14 to day 28 after transplantation either no treatment (n = 11) or ganciclovir, 5 mg/kg twice daily (n = 12). Both groups were similar in age, immunosuppressive therapy, number of acute rejections and in steroid bolus. Seroconversion occurred in ten patients of the control group (91%) and in ten of the ganciclovir group (84%). CMV disease occurred in ten patients of the control group (91%) and in eight patients of the ganciclovir group (66%), three of whom had asymptomatic viraemia. The delay between transplantation and onset of CMV disease was significantly increased by ganciclovir prophylaxis (78.5 +/- 7.7 vs 46.5 +/- 7.5 days, P < 0.05). We conclude that in renal transplant recipients at risk of CMV disease, ganciclovir prophylaxis delays the onset of the disease and seems to decrease its incidence and its severity.
UR - http://www.scopus.com/inward/record.url?scp=17344378692&partnerID=8YFLogxK
U2 - 10.1111/tri.1992.5.s1.30
DO - 10.1111/tri.1992.5.s1.30
M3 - Article
C2 - 14621725
AN - SCOPUS:17344378692
SN - 0934-0874
VL - 5 Suppl 1
SP - S30-31
JO - Transplant international : official journal of the European Society for Organ Transplantation
JF - Transplant international : official journal of the European Society for Organ Transplantation
ER -